AnaptysBio Inc (ANAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AnaptysBio Inc (ANAB) has a cash flow conversion efficiency ratio of -2.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.92 Million) by net assets ($12.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is AnaptysBio Inc's balance sheet to measure how much of total assets are equity-financed.
AnaptysBio Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how AnaptysBio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ANAB cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
AnaptysBio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AnaptysBio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangyin Jianghua Microelectronics Materials Co Ltd
SHG:603078
|
0.030x |
|
NORINCO International Cooperation Ltd
SHE:000065
|
0.069x |
|
Jiangsu New Energy Development Co Ltd
SHG:603693
|
0.063x |
|
ManpowerGroup Inc
NYSE:MAN
|
-0.061x |
|
Zen Technologies Limited
NSE:ZENTEC
|
-0.079x |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
0.001x |
|
Argan SA
PA:ARG
|
0.037x |
|
Bestway Marine & Energy Technology Co Ltd
SHE:300008
|
-0.036x |
Annual Cash Flow Conversion Efficiency for AnaptysBio Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of AnaptysBio Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see AnaptysBio Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $37.21 Million | $19.70 Million | 0.529x | +127.72% |
| 2024-12-31 | $70.87 Million | $-135.34 Million | -1.910x | -39.28% |
| 2023-12-31 | $88.10 Million | $-120.80 Million | -1.371x | -388.33% |
| 2022-12-31 | $262.10 Million | $-73.59 Million | -0.281x | -117.94% |
| 2021-12-31 | $356.43 Million | $-45.92 Million | -0.129x | -261.04% |
| 2020-12-31 | $396.73 Million | $-14.16 Million | -0.036x | +79.21% |
| 2019-12-31 | $405.01 Million | $-69.52 Million | -0.172x | -72.11% |
| 2018-12-31 | $486.37 Million | $-48.51 Million | -0.100x | -57.81% |
| 2017-12-31 | $307.58 Million | $-19.44 Million | -0.063x | +72.52% |
| 2016-12-31 | $39.27 Million | $-9.03 Million | -0.230x | -0.69% |
| 2015-12-31 | $42.34 Million | $-9.67 Million | -0.228x | -109.37% |
| 2014-12-31 | $5.99 Million | $14.60 Million | 2.437x | +106.10% |
| 2013-12-31 | $145.00K | $-5.80 Million | -39.972x | -- |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more